Trial Profile

A Multicenter, Open-label, Randomized Controlled Study of Fruquintinib Combined With TAS-102 Versus Bevacizumab Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic Colorectal Cancer Who Failed Standard Chemotherapy

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 23 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fruquintinib (Primary) ; Tipiracil/trifluridine (Primary) ; Bevacizumab
Indications Adenocarcinoma; Colorectal cancer
Focus Therapeutic Use

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com